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Aim. To investigate the factors contributing to health-related quality of life (HRQOL) in Chinese patients with chronic liver disease
(CLD).Methods.HRQOLwasmeasuredwithSF-36v2Chineseversion.Demographicandclinicaldatawerecollected,andpatients
with liver cirrhosis were divided into Child’s Class A, B, and C according to Child-Turcotte-Pugh scoring system. Results.At o t a l
of 392 Chinese patients with CLD and 91 healthy controls were enrolled. HRQOL in patients with CLD was lower than that in
healthy controls. Score of PCS in healthy controls was 54.6 ± 5.5 and in CLD was 47.8 ± 8.8( P = 0.000). Score of MCS in healthy
controls was 56.4±8.1 and in CLD was 51.7±7.4( P = 0.000). Increasing severity of CLD from no cirrhosis to advanced cirrhosis
was associated with a decrease on all domains of the SF-36 (P<0.05). Stepwise linear regression analysis showed that severity
of disease, age, present ascites, present varices, and prothrombin time had signiﬁcant eﬀect on physical health area. Severity of
disease, female, present varices, total bilirubin, prothrombin time, and hemoglobin had signiﬁcant eﬀect on mental health area.
Conclusions. Patients with CLD had impaired HRQOL. Increasing severity of CLD was associated with a decrease on HRQOL. Old
age, female gender, advanced stage of CLD, present ascites, hyperbilirubinemia, and prolonging prothrombin time were important
factors reducing HRQOL.
1.Introduction
Chronic liver disease (CLD) is increasing being recognized
as an important cause of chronic disease worldwide because
of its epidemiological burden, its potential impact on the
patient’s health, and their health-related quality of life
(HRQOL)[1–4]. Chronic liver disease is also one of the most
common chronic diseases in China, which is responsible
for thousands of dollars per patient per year in direct and
indirect medical costs [5, 6]. Patients with chronic liver
disease suﬀer from fatigue, loss of self-esteem, inability to
function at work, anxiety, depression, and other emotional
problems that profoundly decrease their quality of life and
well-being [7–13]. Many studies on HRQOL in Chinese
patients with CLD are focused on chronic virus hepatitis
B[ 12–14] and few studies on factors contributing to
HRQOL in Chinese patients with CLD. Therefore, we aimed
to investigate factors contributing to HRQOL in Chinese
patients with CLD.
2. Methods
2.1. Ethics. The study received ethics approval from the
Ethics Board of Beijing Chao-Yang Hospital, Capital Medical
University, and all participants gave written informed con-
sent.
2.2. Patient Selection. Between November 2009 and Novem-
ber 2010, all chronic liver disease eligible patients, age 18
to 80 years, both male and female, from the Liver Research
Center of Beijing Friendship Hospital and the Digestive
Department of Beijing Chao-Yang Hospital, Capital Medical
University, were approached for participation in the study.
Patientswithotherchronicactivemedical(suchascongestive
heart failure and chronic obstructive pulmonary disease) or
psychiatric conditions, malignancy, a transplanted liver, and
those unable to communicate or who declined to participate
were excluded. The healthy controls were people without any
chronic diseases, age 18 to 80 years, both male and female,2 Gastroenterology Research and Practice
who regularly took health checkup in our hospital’s health
examination centre.
Each patient had an established diagnosis by a hepatolo-
gist. And the diagnosis of chronic viral hepatitis B was based
on the presence of hepatitis B surface antigen for more than
six months, elevated serum alanine aminotransferase levels,
with or without HBV DNA as detected by the hybridization
method [15]. The diagnosis of chronic viral hepatitis C
was based on a positive hepatitis C antibody (ELISA II
analysis), elevated serum alanine aminotransferase levels,
with or without HCV RNA as detected by polymerase chain
reaction [16]. For both HBV and HCV, patients receiving
interferon therapy in the previous 3 months were also
excluded. The diagnosis of primary biliary cirrhosis was
based on positive antimitochondrial antibody test results
and elevated liver enzymes, with or without liver biopsy
[17]. Alcohol was the etiology of chronic liver disease if
daily alcohol drinking was greater than 40g for at least 10
years, with elevated γ-glutamyl transferase, and ruled out
the possibility of other liver diseases [18]. The diagnosis of
autoimmune hepatitis was based on a simpliﬁed diagnostic
criterion [19]. The diagnosis of liver cirrhosis was based
on clinical, biochemical, serologic, ultrasonographic, and
radiographic parameters. Clinical and laboratory assessment
was conducted to measure the severity of liver cirrhosis
using the Child-Turcotte-Pugh scoring system [20, 21].
The Child-Turcotte-Pugh scoring system included serum
concentrations of total bilirubin and albumin, prothrombin
time, the presence/absence of ascites and encephalopathy.
2.3. Data Collection. At admission, each patient gave his
or her informed consent and then completed the self-
administered HRQOL questionnaire: the Medical Outcomes
Study of Short Form36 (SF-36 v2 Chinese version), a widely
used and validated generic HRQOL questionnaire. Extensive
demographic and clinical data were also collected at this
time.Maritalstatuswasdichotomized intosingleandpaired.
Single was extended to include unmarried person, divorced,
or deceased couple.
Laboratory data included alanine and aspartate amino-
transferases, alkaline phosphatase, γ-glutamyl transferase,
total bilirubin, serum albumin, serum creatine, prothrombin
time, serum potassium and sodium, hemoglobin, white
blood cell, and platelet counts (DADE Dimension Rx1 full-
automatic biochemical analyzer).
2.4. HRQOL Survey. The SF-36 v2 Chinese Version (from
Quality Metric Incorporated) consists of 36 items divided
into eight domains that can be aggregated into two summary
scores, a mental component summary (MCS) and a physical
component summary (PCS). These domains range from
those reﬂecting predominantly physical wellness, including
physical function (PF), the ability to perform expected
physical roles (RP), the degree of bodily pain (BP), and
the overall sense of general health (GH), to those reﬂecting
predominantly social and emotional well-being including
overall sense of vitality (VT), ability to function in social
roles (SF), ability to perform expected emotional and social
roles (RE), and overall sense of mental health (MH). Scores
for these eight SF-36 domains range between 0 and 100,
whereas the summary scores for the physical component
range between 8 and 73 and those for the mental component
range between 10 and 74 [22–24].
2.5. Comparison Groups. There were two groups in our
study: CH (healthy control) and CLD (chronic liver disease).
As far as etiologies of CLD were concerned, there were six
groups: AIH (autoimmune hepatitis), ALD (alcoholic liver
disease),CHB(chronicviralhepatitisB),CHC(chronicviral
hepatitis C), PBC (primary biliary cirrhosis), and unknown
group. And patients with CLD were divided into no cirrhosis
group, CA (Child’s Class A), CB (Child’s Class B), and CC
(Child’s Class C).
2.6. Statistical Methods. A l ld a t aw e r ea n a l y z e dw i t hS P S S
for Windows version 11.0. Categorical data were described
as number and continuous data as mean ±SD, which
were analyzed using independent sample t test or Chi-
square test if suitable. A univariate analysis of general linear
model was used to compare the severity of chronic liver
disease on the domains of SF-36, in which the dependent
variables were SF-36 domains, ﬁxed factor was the group,
and covariates were age and educational level. Stepwise lineal
regression analysis was performed to study the inﬂuence of
independentvariablesondomainsofSF-36whilecontrolling
theeﬀectofothervariables,inwhichthedependentvariables
were domains of SF-36; independents were age, gender,
educational level, marital status, ascites, digestive bleeding,
varices, and other clinical factors. A P value < 0.05 was
considered as statistically signiﬁcant.
3. Results
3.1. Demographic and Clinical Data of Respondents. At o t a l
of 392 Chinese patients with CLD and 91 healthy controls
were enrolled in the study and completed the SF-36 v2. The
demographic and clinical data were shown in Table 1.T h e r e
werenostatisticallysigniﬁcantdiﬀerencesbetweenthegroup
of healthy control and CLD on age, gender, marital status,
and educational level (P>0.05).
Diﬀerent etiologies of chronic liver disease were AIH (34
cases), ALD (112 cases), CHB (105 cases), CHC (63 cases),
PBC (64 cases), and unknown (14 cases). Diﬀerent severities
of chronic liver disease were no cirrhosis (186 cases), CA (49
cases), CB (97 cases), and CC (60 cases).
3.2. Quality of Life in Patients with Chronic Liver Disease.
Table 2 showed scores of SF-36 and clinical data between
healthy control and chronic liver diseases groups. Except BP,
other scores of SF-36 were statistically signiﬁcantly reduced
in chronic liver diseases group. Patients with chronic liver
diseases showed statistically signiﬁcantly decreasing level of
albumin, white blood cell, hemoglobin, and platelet. And
patients with chronic liver diseases also showed statistically
signiﬁcantly increasing level of alanine aminotransferase,
aspartateaminotransferase,alkalinephosphatase,γ-glutamylGastroenterology Research and Practice 3
Table 1: Demographic data of diﬀerent groups.
Items Healthy control Chronic liver disease Independent sample t
test or
n = 91 n = 392 Chi-square
Age (mean ± SD, yr) 53.4 ± 12.7 53.8 ± 13.4 P = 0.806
Male/female (n) 57/34 229/163 P = 0.461
Paired/single (n) 88/3 374/18 P = 0.585
Educational level
(mean ± SD, yr) 11.5 ± 3.4 11.2 ± 3.2 P = 0.408
Etiologies of chronic
liver disease — No cirrhosis Cirrhosis —
CA CB CC
A I H — 1 7 287 —
ALD — 61 5 25 21 —
CHB — 49 17 20 19 —
CHC — 28 11 19 5 —
PBC — 31 11 19 3 —
U n k n o w n — — 365 —
Present ascites — 143 —
Present varices — 181 —
AIH: autoimmune hepatitis, ALD: alcoholic lLiver disease, CHB: chronic hepatitis B, CHC: chronic hepatitis C, PBC: primary biliary cirrhosis. CA: cirrhosis
Class A, CB: cirrhosis Class B, CC: cirrhosis Class C.
transferase, total bilirubin, blood urea nitrogen, and pro-
thrombin time.
Table 3 showed increasing severity of CLD from no cir-
rhosis to advanced cirrhosis (Child’s Class A, Child’s Class B,
toChild’sClassC)wasassociatedwithstatisticallysigniﬁcant
decreasing on all scores of SF-36. Pairwise comparisons
between groups showed scores of Child’s Class C group were
statistically signiﬁcantly reduced.
3.3. The Eﬀect of Demographic and Clinical Characteristics on
Quality of Life. Table 4 showed the results of stepwise linear
regressionanalysisofdiﬀerentdemographicandclinicaldata
on scores of SF-36. The demographic and clinical data in the
stepwise linear regression analysis explained 0.518 and 0.152
onPCSandMCSscoresofSF-36asindicatedbytheRsquare.
Take PCS score; for example, age, disease severity, present
ascites, and prothrombin time had negative eﬀect on PCS.
Our model predicted decreasing score of PCS by 0.129 each
increasing year of life, decreasing score of PCS by 0.385 each
prolonging 1 second of prothrombin time, decreasing score
of PCS by 0.385 in patients with present ascites, decreasing
score of PCS by 2.333 each progressing degree of disease
(from no cirrhosis, Child’s Class A, Child’s Class B to Child’s
Class C).
4. Discussion
We found that patients with chronic liver disease had
impaired HRQOL compared with healthy people, which
agreed with many studies [2–4, 7, 12–15]. Similar scores
on BP resulted from similar scores among healthy control,
no cirrhosis, Child’s A and Child’s B groups only Child’s
C group’s scores of BP were signiﬁcantly reduced. Our
data also found that increasing severity of chronic liver
disease from no cirrhosis to advanced cirrhosis (Child’s
Class C) was associated with a decrease on HRQOL. Other
recent publications also showed that chronic liver diseases
substantially reduced HRQOL; this impact did not diﬀer
markedly by type of disease, and increasing disease severity
was associated with poorer HRQOL, especially relating
to a physical component [2–4, 10–13, 25–31]. With the
progressing of liver dysfunction, patients with CLD suﬀer
from fatigue, loss of self-esteem, inability to function at
work, anxiety, depression, and other emotional problems
that profoundly decrease their quality of life and well-
being [22, 32]. Patients with liver cirrhosis also suﬀer from
complications, which will reduce their HRQOL, especially
on physical domain area for their diﬃculty to maintain daily
work and life [22–24, 32–36].
Our study evaluated the factors contributing to HRQOL
in Chinese patients with CLD, such as age, gender, marital
status, educational level, and laboratory data. Stepwise linear
regression analysis showed that increasing disease severity
reduced patients’ PF, RP, GH, VT, SF, and PCS. Aging had
negative eﬀect on multiple domains, especially on physical
domains. And female gender had negative eﬀect on multiple
domains, especially on mental domains; possible cause was
that female patients paid more attention on their health
and spent more time on consulting treatment. Marital status
had positive eﬀect on GH, because married patients with4 Gastroenterology Research and Practice
Table 2: HRQOL and clinical data of diﬀerent groups.
Item Healthy control Chronic liver
disease Independent
sample t test
n = 91 n = 392
Physical
function 92.5 ± 6.6 80.6 ± 21.6 P<0.001
Physical roles 93.0 ± 11.8 73.7 ± 24.2 P<0.001
Bodily pain 86.9 ± 15.5 83.8 ± 19.0 P = 0.108
General health 76.2 ± 18.0 49.9 ± 23.2 P<0.001
Vitality 83.4 ± 11.8 73.4 ± 14.6 P<0.001
Social roles 94.2 ± 10.4 77.6 ± 22.9 P<0.001
Emotional roles 92.7 ± 10.8 86.9 ± 17.4 P<0.001
Mental health 87.5 ± 24.5 77.2 ± 14.1 P<0.001
PCS 54.6 ± 5.5 47.8 ± 8.8 P<0.001
MCS 56.4 ± 8.1 51.7 ± 7.4 P<0.001
Laboratory data
Albumin (g/L) 36.3 ± 2.8 33.3 ± 7.8
(n = 330) P<0.001
ALT (U/L) 22.5 ± 9.1 53.2 ± 60.8
(n = 328) P = 0.006
AST (U/L) 22.5 ± 10.7 66.7 ± 71.9
(n = 328) P<0.001
GGT (U/L) 49.5 ± 51.6 101.6 ± 163.7
(n = 323) P<0.001
ALP (U/L) 99.1 ± 8.1 127.3 ± 88.9
(n = 323) P = 0.001
TBIL (mg/dL) 0.57 ± 0.27 1.96 ± 2.58
(n = 323) P<0.001
BUN (umol/L) 5.1 ± 0.9 6.0 ± 3.9
(n = 329) P<0.001
K (umol/L) 4.00 ± 0.28 4.03 ± 0.48
(n = 329) P = 0.531
Na (umol/L) 140.2 ± 3.41 146.1 ± 8.63
(n = 329) P = 0.092
Prothrombin
Time (s) 10.4 ± 0.4 14.2 ± 3.8
(n = 329) P<0.001
WBC (109/L) 5.93 ± 1.56 4.72 ± 2.69
(n = 330) P<0.001
Hemoglobin
(g/L) 138.1 ± 22.2 113.6 ± 27.4
(n = 330) P<0.001
Platelet (109/L) 206.0 ± 44.3 115.6 ± 69.2
(n = 330) P<0.001
PCS: physical component summary, MCS: mental component summary
ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP:
alkaline phosphatase, GGT: γ-glutamyl transferase, TBIL: total bilirubin,
BUN: blood urea nitrogen, K: serum potassium, Na: serum sodium, WBC:
white blood cell.
CLD could get psychological support from their partner.
Present ascites had negative eﬀect on patients’ PF and PCS,
for patients with ascites ﬁnding it diﬃcult to maintain
daily work and life. And patients with varices lose function
to do daily work and had impaired RP and RE. Level of
hemoglobin had positive eﬀect on SF and MH because
patients with normal hemoglobin could take part in social
activities (visiting relatives and friends). BUN also had
positiveeﬀectonMCS.Liverfailurecancausemalabsorption
of nutrition, insuﬃcient intake, and massive consumption
of protein, which cause reduced BUN and negative nitrogen
balance, while high value of BUN within normal range
suggested positive nitrogen balance and relatively better liver
function. Prolonged prothrombin time had negative eﬀect
on multiple domains of HRQOL because patients with poor
prothrombin function reduced their ability on physical,
social, and mental domains. Recent studies [22, 25, 36–41]
supported our ﬁndings that aging, female gender, present
ascites,andprolongingprothrombintimehadnegativeeﬀect
onHRQOL.Potentialtreatablefactors[42–44],correctionof
ascites, hypoalbuminemia, minimal hepatic encephalopathy,
and anemia, eating BCAA-enriched snack and long-term
late-evening snack may cause a positive impact on HRQOL
in patients with CLD.
We also found etiology had no eﬀect on HRQOL in
patients with CLD. But some researches [11, 12, 37, 45]
suggested that patients with primary biliary cirrhosis had
impaired HRQOL than other liver diseases. However, we got
support from researches [25–29] that diﬀerent etiologies of
liver disease had similar HRQOL.
There are two basic types of HRQOL questionnaires,
which measure HRQOL from the patient perspective:
generic questionnaires and disease-speciﬁc questionnaires.
A third type of HRQOL questionnaire exists from a cost-
eﬀectiveness perspective, called utility measures. In this
study, we used SF-36v2, a widely used generic questionnaire,
to measure the HRQOL in Chinese patients with chronic
liver disease and to compare it with Chinese healthy controls.
SF-36 is a short and easy questionnaire; it only takes patients
several minutes to complete and can be used in developing
countries and provide information that is complementary to
the clinical data. HRQOL measures, such as SF-36, can help
to integrate the biomedical and the psychosocial models of
health. This integrated approach to the study of chronic liver
disease will capture the impact of these diseases on patients’
health and well-being [22–24, 32–36].
Our study has some limitations. All subjects were
recruited from two hospitals in one city, which might have
potential selection bias. Our study included patients with
a wide spectrum of disease severity (from no cirrhosis to
Child’s Class C) and diﬀerent etiologies (AIH, ALD, CHB,
CHC, and PBC), and the number of patients is relatively
less. We are addressing these issues in ongoing studies and
will assess more patients in more centers, explore SF-36 in
more patients with CLD, and take into account the economic
income and burden of the patients. And we also want to
reevaluate the HRQOL after medical treatment.
In summary, patients with CLD had impaired HRQOL,
andincreasingseverityofCLDwasassociatedwithadecrease
on HRQOL. Old age, female gender, advanced stage of
CLD, present ascites, hyperbilirubinemia, and prolonging
prothrombin time were important factors reducing HRQOL.
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Table 3: HRQOL scores of patients with diﬀerent severities of CLD (mean ± SD).
SF-36 Dimension No cirrhosis CA CB CC Univariate aAnalysis
of variance n = 186 n = 49 n = 97 n = 60
PF 91.7 ± 9.3c,d 85.2 ± 17.8c,d 72.4 ± 21.5a,b,d 55.7 ± 25.9a,b,c P<0.001
RP 88.2 ± 13.2b,c,d 73.3 ± 22.2a,c,d 61.6 ± 21.5a,b,d 48.7 ± 25.8a,b,c P<0.001
BP 88.5 ± 13.6d 85.8 ± 17.4d 83.5 ± 19.4d 68.3 ± 25.2a,b,c P<0.001
GH 63.5 ± 18.5b,c,d 55.1 ± 20.1a,c,d 35.1 ± 16.7a,b 29.0 ± 18.3a,b P<0.001
VT 79.0 ± 9.5b,c,d 74.3 ± 13.1a,d 70.8 ± 13.1a,d 59.3 ± 20.1a,b,c P<0.001
SF 89.1 ± 14.1c,d 83.1 ± 18.4c,d 66.2 ± 15.8a,b,d 55.2 ± 25.1a,b,c P<0.001
RE 92.4 ± 9.8c,d 86.2 ± 15.8d 84.6 ± 17.9a,d 74.2 ± 26.8a,b,c P<0.001
MH 78.4 ± 10.6d 80.1 ± 11.3d 79.2 ± 12.8d 67.8 ± 21.8a,b,c P<0.001
PCS 53.1 ± 5.9b,c,d 48.7 ± 6.6a,c,d 42.4 ± 7.1a,b,d 37.2 ± 8.9a,b,c P<0.001
MCS 53.2 ± 4.8d 52.7 ± 6.5d 51.8 ± 7.5d 46.8 ± 7.5a,b,c P<0.001
Mean age = 53.83, mean educational level = 11.19. CLD: chronic liver disease, CA: cirrhosis Class A, CB: cirrhosis Class B, CC: cirrhosis Class C, PF:
physical function, RP: physical roles, BP: bodily pain, GH: general health, VT: vitality, SF: social roles, RE: emotional roles, MH: mental health, PCS: physical
component summary, MCS: mental component summary, SF-36: 36-item short form. Pairwise comparisons: aP<0.05 versus no cirrhosis, bP<0.05 versus
CA, cP<0.05 versus CB, dP<0.05 versus CC.
Table 4: Results of stepwise linear regression analysis.
Item
SF-36 Dimension and unstandardized coeﬃcients (n = 411)
PF RP BP GH VT SF RE MH PCS MCS
Constant 137.773 124.686 113.618 70.895 92.104 92.052 99.491 103.914 67.407 59.778
Age −0.398 −0.247 −0.140 — — −0.161 −0.181 — −0.129 —
Gender −3.216 — — — −3.023 — — −4.295 — −1.673
M a r r i e d——— 1 3 . 6 2 8 ———— — —
Disease
Severity
−2.912 −6.016 −11.670 −4.111 −5.881 — — −2.333 —
Ascites −7 . 6 1 6 ——————— −3.001 —
Varices — −6 . 3 8 9 ———— −4.370 — — —
B U N ———————— — 0 . 3 3 0
H e m o g l o b i n ————— 0 . 1 3 6 —— — 0 . 3 1 2
E t i o l o g y———————— — —
PT −1.488 −1.253 −1.681 — — −0.999 −1.209 −1.238 −0.385 −0.767
K —————— 3 . 9 8 4 — — —
N a ———————— — —
T B I L ———— −1.147 — — −0.894 —
A l b u m i n———————— — —
A L T ———————— — —
A S T ———————— — —
G G T ———————— — —
A L P ———————— — —
W B C ———————— — —
P l a t e l e t ———————— — —
R square 0.458 0.438 0.121 0.460 0.256 0.375 0.181 0.111 0.518 0.152
BUN:bloodureanitrogen,PT:prothrombintime,K:serumpotassium,Na:serumsodium,TBIL:totalbilirubin,ALT:alanineaminotransferase,AST:aspartate
aminotransferase, ALP: alkaline phosphatase, GGT: γ-glutamyl transferase, WBC: white blood cell. PF: physical function, RP: physical roles, BP: bodily pain,
GH: general health, VT: vitality, SF: social roles, RE: emotional roles, MH: mental health, PCS: physical component summary, MCS: mental component
summary, SF-36: 36-item short form. Only data with P<0.05 were expressed as values of beta-coeﬃcients. “—”: P>0.05.6 Gastroenterology Research and Practice
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